{"slug":"glp1-obesity","as_of":"2026-10-22","verified_at":"2026-10-22","languages":{"zh":{"title":"台灣 GLP-1 與減重藥相關開發公司總表","summary":[{"text":"截至2026年10月22日，本表收錄7家台灣公司的GLP-1或減重相關藥物、原料藥與授權開發項目。","source_urls":["https://www.scinopharm.com/news-detail/144/","https://www.formosalab.com/storage/architecture/page~139/page~142/page~210/20260313.pdf","https://mopsov.twse.com.tw/nas/STR/176220260910M002.pdf","https://onenessbio.com/wp-content/uploads/2026/08/2026第二次法說會_final_中文上傳版.pdf","https://www.caliwaybiopharma.com/document-detail/0/110/","https://api.lotuspharm.com/shareholders-meeting/download?id=14&index=3&locale=en","https://mopsov.twse.com.tw/nas/STR/655020251211M001.pdf"]},{"text":"所列SNS851已進入一期，CBL-514與tirzepatide合併案取得二期IND許可；原料藥DMF、授權協議及產線開發均另列，沒有當成成品藥上市核准。","source_urls":["https://www.scinopharm.com/news-detail/144/","https://www.formosalab.com/storage/architecture/page~139/page~142/page~210/20260313.pdf","https://mopsov.twse.com.tw/nas/STR/176220260910M002.pdf","https://onenessbio.com/wp-content/uploads/2026/08/2026第二次法說會_final_中文上傳版.pdf","https://www.caliwaybiopharma.com/document-detail/0/110/","https://api.lotuspharm.com/shareholders-meeting/download?id=14&index=3&locale=en","https://mopsov.twse.com.tw/nas/STR/655020251211M001.pdf"]}],"undisclosed":"本表涵蓋原料藥、成品藥與授權合作，各列角色與階段不等同；來源未揭露的品名、申請適應症、臨床期別或確定核准日均不填補。"},"en":{"title":"Taiwan GLP-1 and Obesity-Related Development Companies","summary":[{"text":"As of October 22, 2026, this table includes GLP-1 or weight-management drug, API and licensing-development projects at 7 Taiwan companies.","source_urls":["https://www.scinopharm.com/news-detail/144/","https://www.formosalab.com/storage/architecture/page~139/page~142/page~210/20260313.pdf","https://mopsov.twse.com.tw/nas/STR/176220260910M002.pdf","https://onenessbio.com/wp-content/uploads/2026/08/2026第二次法說會_final_中文上傳版.pdf","https://www.caliwaybiopharma.com/document-detail/0/110/","https://api.lotuspharm.com/shareholders-meeting/download?id=14&index=3&locale=en","https://mopsov.twse.com.tw/nas/STR/655020251211M001.pdf"]},{"text":"The selected SNS851 program has entered Phase 1, and the CBL-514 plus tirzepatide program has Phase 2 IND clearance; API DMFs, license agreements and production-line development are kept separate from finished-drug approval.","source_urls":["https://www.scinopharm.com/news-detail/144/","https://www.formosalab.com/storage/architecture/page~139/page~142/page~210/20260313.pdf","https://mopsov.twse.com.tw/nas/STR/176220260910M002.pdf","https://onenessbio.com/wp-content/uploads/2026/08/2026第二次法說會_final_中文上傳版.pdf","https://www.caliwaybiopharma.com/document-detail/0/110/","https://api.lotuspharm.com/shareholders-meeting/download?id=14&index=3&locale=en","https://mopsov.twse.com.tw/nas/STR/655020251211M001.pdf"]}],"undisclosed":"API, finished-drug and licensing roles and stages are distinct. Product names, filing indications, clinical phases and confirmed approval dates absent from the cited sources remain unfilled."}},"companies":[{"company":"神隆","company_en":"ScinoPharm Taiwan","ticker":"1789","product":"減重針劑／GLP-1糖尿病針劑（品名與代號查無）","product_en":"Weight-management injection / GLP-1 diabetes injection (names and codes undisclosed)","indication":"體重管理；糖尿病","indication_en":"Weight management; diabetes","stage":"減重針劑已提交美國申請；糖尿病針劑審查中（公告未明地區）","stage_en":"U.S. weight-management drug application filed; diabetes injection under review (jurisdiction unspecified)","as_of":"2026-08-17","source":"https://www.scinopharm.com/news-detail/144/","quote":"submitted a U.S. drug application","company_source":"https://openapi.twse.com.tw/v1/opendata/t187ap03_L","company_quote":"台灣神隆股份有限公司","catalyst":null},{"company":"台耀","company_en":"Formosa Laboratories","ticker":"4746","product":"Semaglutide 針劑（原簡報拼為 Semagultide）","product_en":"Semaglutide injection (spelled Semagultide in source)","indication":"GLP-1 藥物；具體申請適應症查無","indication_en":"GLP-1 medicine; specific filing indications not disclosed","stage":"劑型開發進行中；商業與組裝產線建置中","stage_en":"Formulation development; commercial and assembly lines under construction","as_of":"2026-03-13","source":"https://www.formosalab.com/storage/architecture/page~139/page~142/page~210/20260313.pdf","quote":"劑型開發進行中","company_source":"https://openapi.twse.com.tw/v1/opendata/t187ap03_L","company_quote":"台耀化學股份有限公司","catalyst":null,"date_basis":"簡報封面Mar13,2026；頁尾顯示2026/3/12。所列進度見第21頁。"},{"company":"中化生","company_en":"Chunghwa Chemical Synthesis & Biotech","ticker":"1762","product":"Setmelanotide Acetate（原料藥）","product_en":"Setmelanotide acetate API","indication":"基因肥胖症","indication_en":"Genetic obesity","stage":"列為美國DMF註冊原料藥41490；非成品藥核准","stage_en":"Listed as U.S. DMF-registered API 41490; not a finished-drug approval","as_of":"2026-09-16","source":"https://mopsov.twse.com.tw/nas/STR/176220260910M002.pdf","quote":"SETMELANOTIDE ACETATE","company_source":"https://openapi.twse.com.tw/v1/opendata/t187ap03_L","company_quote":"中化合成生技股份有限公司","catalyst":null,"source_page":5,"date_basis":"封面2026-09-16；第5頁US DMF註冊產品與第12頁適應症均視覺核對。"},{"company":"合一","company_en":"Oneness Biotech","ticker":"4743","product":"SNS851（siRNA，非GLP-1促效劑）","product_en":"SNS851 (siRNA; not a GLP-1 agonist)","indication":"肥胖與代謝疾病相關減重開發","indication_en":"Obesity and metabolic disease-related weight-management development","stage":"澳洲一期；已完成單劑量給藥，2026年8月啟動多劑量組","stage_en":"Australian Phase 1; single dosing completed and multiple dosing started in August 2026","as_of":"2026-08-21","source":"https://onenessbio.com/wp-content/uploads/2026/08/2026第二次法說會_final_中文上傳版.pdf","quote":"2026.08啟動","company_source":"https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O","company_quote":"合一生技股份有限公司","catalyst":{"text":"2026年8月法說預定於2026年第4季完成SNS851所有受試者給藥；尚未核實完成。","text_en":"The August 2026 presentation planned completion of SNS851 dosing in Q4 2026; completion is not verified.","as_of":"2026-08-21","source":"https://onenessbio.com/wp-content/uploads/2026/08/2026第二次法說會_final_中文上傳版.pdf","quote":"預定2026.Q4完成所有受試者給藥"},"source_page":39},{"company":"康霈*","company_en":"Caliway Biopharmaceuticals","ticker":"6919","product":"CBL-514＋tirzepatide（CBL-0201WR）","product_en":"CBL-514 plus tirzepatide (CBL-0201WR)","indication":"減少過重或肥胖成人腹部皮下脂肪","indication_en":"Reduction of abdominal subcutaneous fat in overweight or obese adults","stage":"第2期IND已獲FDA核准執行；未以IND推定首位給藥","stage_en":"Phase 2 IND cleared by FDA; first dosing not inferred","as_of":"2026-08-31","source":"https://www.caliwaybiopharma.com/document-detail/0/110/","quote":"CBL-0201WR Ph2 study:  IND已核准","company_source":"https://openapi.twse.com.tw/v1/opendata/t187ap03_L","company_quote":"康霈生技股份有限公司","catalyst":null,"source_page":11},{"company":"美時","company_en":"Lotus Pharmaceutical","ticker":"1795","product":"Semaglutide針劑（Wegovy／Ozempic 2mg學名藥合作案）","product_en":"Semaglutide injection (Wegovy / Ozempic 2 mg generic partnership)","indication":"查無（此年報段落未細分申請適應症）","indication_en":"Specific filing indications not disclosed in this annual-report passage","stage":"已與Adalvo簽授權及供貨協議；此段未揭露臨床期別","stage_en":"License and supply agreement with Adalvo signed; clinical phase not specified","as_of":"2026-10-22","source":"https://api.lotuspharm.com/shareholders-meeting/download?id=14&index=3&locale=en","quote":"License and Supply Agreement with Adalvo","company_source":"https://openapi.twse.com.tw/v1/opendata/t187ap03_L","company_quote":"美時化學製藥股份有限公司","catalyst":null,"source_page":6,"date_basis":"2025年報公開檔於2026-10-22查閱；未把授權簽署推定為臨床試驗或藥證進度。"},{"company":"北極星藥業-KY","company_en":"Polaris Group","ticker":"6550","product":"Semaglutide／Tirzepatide（原料藥與製劑產品線）","product_en":"Semaglutide / tirzepatide API and formulation pipeline","indication":"糖尿病、肥胖／減重","indication_en":"Diabetes; obesity / weight management","stage":"產品線與製劑開發布局；未揭露臨床期別","stage_en":"API and formulation development pipeline; clinical phase undisclosed","as_of":"2025-12-11","source":"https://mopsov.twse.com.tw/nas/STR/655020251211M001.pdf","quote":"具備針劑/口服製劑開發與生產能力","company_source":"https://openapi.twse.com.tw/v1/opendata/t187ap03_L","company_quote":"北極星藥業集團股份有限公司","catalyst":null,"source_page":35,"date_basis":"同來源第37、40頁列產品與適應症；不以產線能力推定任何成品上市核准。"}],"scope":{"not_exhaustive":true,"coverage":"Source-verified selection from existing Taiwan company profiles; one row per company, with one named program or service selected for that company.","stage_basis":"Stage is the statement in the cited source as of its stated date; an undated live page uses the access date. Development, trial authorization, recruitment and marketing authorization remain separate.","count_basis":"Company rows, not an industry-wide census or a count of independent drugs. Licensed products, original development and customer manufacturing are identified in product and stage fields."}}